Connect Biopharma to Participate at the Jefferies Healthcare Conference
Connect Biopharma Holdings Limited (Nasdaq: CNTB) announced that Dr. Zheng Wei and CFO Steven Chan will participate in a fireside chat at the Jefferies Healthcare Conference on June 10, 2022, at 10:30 am ET. A live webcast will be available on the Company’s Investor Relations page, with a replay post-event. Connect Biopharma focuses on therapies for chronic inflammatory diseases, leveraging T cell-driven research, including its lead product CBP-201 for treating atopic dermatitis and asthma. The company is advancing multiple candidates targeting T cell biology in the U.S. and China.
- None.
- None.
SAN DIEGO, CA and TAICANG, SUZHOU, China, June 02, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that Dr. Zheng Wei, Co-Founder & Chief Executive Officer, and Steven Chan, Chief Financial Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Friday, June 10, 2022 at 10:30 am ET.
A live webcast will be available on the Company’s Investor Relations page, accessible here: https://investors.connectbiopharm.com/. A replay will be available on the Company’s website following the event.
About Connect Biopharma Holdings Limited
Connect Biopharma is a global, clinical-stage biopharmaceutical company dedicated to improving the lives of patients with inflammatory diseases through the development of therapies derived from T cell-driven research. It is building a rich pipeline of internally-designed, wholly-owned, small molecules and antibodies using functional cellular assays with T cells to screen and discover potent product candidates against validated immune targets. Its lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. The Company’s second most advanced product candidate, CBP-307, is a modulator of a T-cell receptor known as S1P1 in development for the treatment of UC. Clinical development has begun for its third product candidate, CBP-174, a peripherally acting antagonist of histamine receptor 3, for the treatment of pruritus associated with AD.
With operations in the United States and China, Connect Biopharma is building a rich global pipeline of molecules and antibodies targeting several aspects of T cell biology. For additional information, please visit www.connectbiopharm.com.
IR/PR CONTACTS:
Lazar FINN Partners
David Carey (IR)
T: +1 (212) 867-1768
david.carey@finnpartners.com
Glenn Silver (Media)
T: +1 (973) 818-8198
glenn.silver@finnpartners.com
Corporate Contacts:
info@connectpharm.com
FAQ
What is the date of the Jefferies Healthcare Conference participation by Connect Biopharma?
Who are the Connect Biopharma executives participating in the fireside chat?
What is the ticker symbol for Connect Biopharma?
What is the primary focus of Connect Biopharma?
What are the key product candidates of Connect Biopharma?
